Current drug targets · 2026
Nucleic Acid Foundation Models for siRNA Drug Design.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ren Liping, Zulfiqar Hasan, Shi Zheng, Xu Guangya, Zhang Yang, Luo Nanchao
Аннотация
BACKGROUND: Small interfering RNA (siRNA) therapeutics have become an important class of nucleic acid medicines. Meanwhile, nucleic acid foundation models and RNA language models have demonstrated promising performance in selected RNA-related tasks and may support siRNA drug design through transferable sequence representation learning.
APPROACH: This mini-review selectively surveys and critically evaluates representative nucleic acid foundation models and their potential roles in siRNA design, including representation learning, lowdata adaptation, multitask prediction, generative design, and multi-objective optimization. Particular attention is given to RNA language models such as RNA-FM and RiNALMo, while DNA, regulatory, unified DNA-RNA, and multimodal models are positioned according to their direct or contextual relevance to siRNA development.
RESULTS: Current models can be broadly grouped into DNA genomic language models, RNA language models, epigenomic/regulatory models, unified DNA-RNA models, and multimodal biomolecular foundation models. Across these categories, existing models provide complementary capabilities for sequence, structure, regulatory context, and cross-modal representation, but none yet constitutes a complete framework for therapeutic siRNA design.
DISCUSSION: Although these models show strong transferability across genomic and RNA tasks, their value for siRNA-specific therapeutic design remains insufficiently established. A central challenge is the mismatch between the natural RNA grammar and the therapeutic oligonucleotide grammar. Real siRNA development requires simultaneous consideration of efficacy, specificity, chemical modification, stability, immunogenicity, off-target effects, delivery compatibility, and manufacturability.
CONCLUSION: Future progress will depend on modification-aware representations, therapeutic oligonucleotide datasets, multimodal integration, interpretable and experimentally testable outputs, robust cross-dataset and cross-protocol evaluation, and Pareto-based multi-objective selection. These requirements define a practical roadmap for moving from transferable RNA representations to therapeutically credible siRNA design systems.
APPROACH: This mini-review selectively surveys and critically evaluates representative nucleic acid foundation models and their potential roles in siRNA design, including representation learning, lowdata adaptation, multitask prediction, generative design, and multi-objective optimization. Particular attention is given to RNA language models such as RNA-FM and RiNALMo, while DNA, regulatory, unified DNA-RNA, and multimodal models are positioned according to their direct or contextual relevance to siRNA development.
RESULTS: Current models can be broadly grouped into DNA genomic language models, RNA language models, epigenomic/regulatory models, unified DNA-RNA models, and multimodal biomolecular foundation models. Across these categories, existing models provide complementary capabilities for sequence, structure, regulatory context, and cross-modal representation, but none yet constitutes a complete framework for therapeutic siRNA design.
DISCUSSION: Although these models show strong transferability across genomic and RNA tasks, their value for siRNA-specific therapeutic design remains insufficiently established. A central challenge is the mismatch between the natural RNA grammar and the therapeutic oligonucleotide grammar. Real siRNA development requires simultaneous consideration of efficacy, specificity, chemical modification, stability, immunogenicity, off-target effects, delivery compatibility, and manufacturability.
CONCLUSION: Future progress will depend on modification-aware representations, therapeutic oligonucleotide datasets, multimodal integration, interpretable and experimentally testable outputs, robust cross-dataset and cross-protocol evaluation, and Pareto-based multi-objective selection. These requirements define a practical roadmap for moving from transferable RNA representations to therapeutically credible siRNA design systems.